Centuple Global Ltd vs SUN PHARMACEUTICAL IND L

A side-by-side comparison of Centuple Global Ltd (RUBRAMEDICAMENTSLTD) and SUN PHARMACEUTICAL IND L (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, SUN PHARMACEUTICAL IND L leads RUBRAMEDICAMENTSLTD vs SUNPHARMA on 9 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability04
  • Growth10
  • Size & financial health13
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

16.80
P/E ratio
40.36
0.90
P/B ratio
20.07
0.00%
Dividend yield
0.84%
₹0.05
EPS
₹47.84

Profitability

SUNPHARMA takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

12.70%
Return on equity
16.00%
17.00%
Return on capital
21.00%
20.00%
EBITDA margin
30.00%
0.00%
Net margin
19.69%

Growth

RUBRAMEDICAMENTSLTD takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

730.98%
Revenue CAGR (3Y)
10.03%
Profit CAGR (3Y) even
10.57%

Size & financial health

SUNPHARMA takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹20 Cr
Market cap
₹4.63L Cr
₹0 Cr
Revenue
₹58,462 Cr
₹0 Cr
Net profit
₹11,509 Cr
0.30
Debt / equity
0.61
Centuple Global Ltd
  • + ["Stock is trading at 0.87 times its book value", "Company's median sales growth is 26.2% of last 10 years", "Company's working capital requirements have reduced from 182 days to 14.7 days"]
  • ["Though the company is reporting repeated profits, it is not paying out dividend", "Company has a low return on equity of 12.3% over last 3 years.", "Company might be capitalizing the interest cost", "Company has high debtors of 215 days."]
SUN PHARMACEUTICAL IND L
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
Centuple Global Ltd full analysis SUN PHARMACEUTICAL IND L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

RUBRAMEDICAMENTSLTD vs SUNPHARMA: Share Price, Valuation & Which to Buy | DocStoX